Estimates and predictors of healthcare costs of esophageal adenocarcinoma: a population-based cohort study
Thein HH, Jembere N, Thavorn K, Chan KKW, Coyte PC, de Oliveira C, Hur C, Earle CC. BMC Cancer. 2018; 18(1):694. Epub 2018 Jun 27.
Publications
The economic burden of cancer care in Canada: a population-based cost study
de Oliveira C, Weir S, Rangrej J, Krahn MD, Mittmann N, Hoch JS, Chan KKW, Peacock S. CMAJ Open. 2018; 6(1):E1-10. Epub 2018 Jan 4.
Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013
Gong IY, Yan AT, Ko DT, Earle CC, Cheung WY, Peacock S, Hall M, Gale CP, Chan KKW. Cancer. 2018; 124(6):1269-78. Epub 2017 Dec 6.
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting
Thein HH, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. PLoS One. 2017; 12(10):e0185198.
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting
Thein HH, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Cancer Med. 2017; 6(9):2017-33. Epub 2017 Aug 8.
Association between cardiovascular risk factors and aortic stenosis: the CANHEART aortic stenosis study
Yan AT, Koh M, Chan KK, Guo H, Alter DA, Austin PC, Tu JV, Wijeysundera HC, Ko DT. J Am Coll Cardiol. 2017; 69(12):1523-32.
Estimating the cost of cancer care in British Columbia and Ontario: a Canadian inter-provincial comparison
de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KKW, Cheung WY, Hoch JS, Peacock S, Krahn MD. Healthc Policy. 2017; 12(3):95-108.
Phase-specific and lifetime costs of cancer care in Ontario, Canada
de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, Hoch JS, Peacock S, Krahn MD. BMC Cancer. 2016; 16:809. Epub 2016 Oct 18.
Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study
Gong IY, Verma S, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Brezden-Masley CB, Gavura S, Peacock S, Chan KK. Breast Cancer Res Treat. 2016; 157(3):535-44. Epub 2016 Jun 6.
The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study
Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK. J Natl Cancer Inst. 2016; 108(1):djv301. Epub 2015 Oct 16.